Real-world study of PD-1/L1 immune checkpoint inhibitors for advanced non-small cell lung cancer after resistance to EGFR-TKIs

BACKGROUND: Programmed cell death-1 (PD-1) and its ligand 1 (PD-L1) inhibitors have achieved good efficacy and safety in patients with advanced EGFR mutation-negative non-small cell lung cancer (NSCLC), but their efficacy in patients with previous EGFR mutations is limited. The aim of the present st...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Kunchen, Zhou, Chao, Chen, Yang, Feng, Xiao, Tang, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392920/
https://www.ncbi.nlm.nih.gov/pubmed/37534246
http://dx.doi.org/10.3389/fonc.2023.1217872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392920/
https://www.ncbi.nlm.nih.gov/pubmed/37534246
http://dx.doi.org/10.3389/fonc.2023.1217872

Ejemplares similares